187 related articles for article (PubMed ID: 21528407)
1. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.
Fathi M; Amirghofran Z; Shahriari M
Med Oncol; 2012 Sep; 29(3):2046-52. PubMed ID: 21528407
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.
Boroumand-Noughabi S; Sima HR; Ghaffarzadehgan K; Jafarzadeh M; Raziee HR; Hosseinnezhad H; Moaven O; Rajabi-Mashhadi MT; Azarian AA; Mashhadinejad M; Tavakkol-Afshari J
BMC Cancer; 2010 Jun; 10():275. PubMed ID: 20534173
[TBL] [Abstract][Full Text] [Related]
3. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
[TBL] [Abstract][Full Text] [Related]
4. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies.
Hazar V; Berber Z; Pestereli E; Coskun M; Yesilipek A; Karpuzoglu G; Yegin O
Pediatr Hematol Oncol; 2005; 22(3):247-56. PubMed ID: 16020109
[TBL] [Abstract][Full Text] [Related]
5. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis.
Musiał K; Zwolińska D
Apoptosis; 2011 Jul; 16(7):653-9. PubMed ID: 21516345
[TBL] [Abstract][Full Text] [Related]
7. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
[TBL] [Abstract][Full Text] [Related]
8. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
Codony-Servat J; Garcia-Albeniz X; Pericay C; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Martínez-Cardús A; Martinez-Balibrea E; Maurel J
Med Oncol; 2013 Mar; 30(1):428. PubMed ID: 23338968
[TBL] [Abstract][Full Text] [Related]
9. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
11. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
12. [Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].
Yuan BJ; Liu ZZ; Ding XR; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 Feb; 24(2):96-8. PubMed ID: 16600114
[TBL] [Abstract][Full Text] [Related]
13. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M
Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas/FasLare elevated in the serum and cerebrospinal fluid of patients with neurocysticercosis.
Chen X; Yu X; Wang Y; Zhu J; Gu J
Parasitol Res; 2017 Nov; 116(11):3027-3036. PubMed ID: 28965226
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
Soni S; Rath G; Deval R; Salhan S; Mishra AK; Saxena S
Am J Reprod Immunol; 2011 Sep; 66(3):230-6. PubMed ID: 21385271
[TBL] [Abstract][Full Text] [Related]
16. Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.
Guzmán-Fulgencio M; Berenguer J; García-Álvarez M; Micheloud D; C López J; Cosín J; Fernández de Castro I; Catalán P; Miralles P; Resino S
Eur J Clin Microbiol Infect Dis; 2011 Oct; 30(10):1213-21. PubMed ID: 21442358
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
Jun EJ; Han JY; Sun HS
Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
[TBL] [Abstract][Full Text] [Related]
18. Temporal evolution of soluble Fas and Fas ligand in patients with orthotopic liver transplantation.
Wang Y; Liu Y; Han R; Yang J; Zhu Z; Zhang Y; Yao Z; Gao W; Shen Z
Cytokine; 2008 Mar; 41(3):240-3. PubMed ID: 18267366
[TBL] [Abstract][Full Text] [Related]
19. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
Sugita S; Taguchi C; Takase H; Sagawa K; Sueda J; Fukushi K; Hikita N; Watanabe T; Itoh K; Mochizuki M
Br J Ophthalmol; 2000 Oct; 84(10):1130-4. PubMed ID: 11004098
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]